Juniper to automate Divi’s Labs API facilities

By Ben Hargreaves

- Last updated on GMT

© Getty Images
© Getty Images

Related tags API Active pharmaceutical ingredients Manufacturing facility

Juniper will work with Divi’s Labs to provide networking solutions across its API manufacturing network, aiming to improve operational efficiencies.

Divi’s Laboratories is an active pharmaceutical ingredient (API) manufacturer, headquartered in Hyderabad, India. The company owns two Indian manufacturing sites, one located near Hyderabad and one in Visakhapatnam.

According to Divi’s Labs, the two sites make up the largest API manufacturing facilities globally, with a total of 14,500-aquare-meter manufacturing space across over 64 buildings at the two sites.

Juniper Networks, a US company that provides ‘AI-driven networks’, will be responsible for implementing a secure, ‘ultra-reliable’ network that can securely transfer data at line rate between the plants without any packet loss.

Divi's Labs sustainability commitments

Divi’s Labs stated that it had chosen to work with Juniper “after experiencing difficulties managing and monitoring its network with [its] previous legacy solution.”

The partners stated that the agreement would see the network include Power-over-Ethernet (PoE) and PoE+ switching to provide wireless infrastructure, whilst also allowing organizational-wide network visibility, easy onboarding and manageability.

The demands of the sites means that Divi’s Labs requires high-capacity uplinks and multigigabit downlinks to meet data exchange needs, as well as the ability to reduce power consumption to meet Devi’s Labs sustainability commitments.

Mission critical network services

“With our manufacturing operations running 24/7, network services are mission-critical with any disruptions having the potential to cause significantly negative impact on production. We are delighted to have found a partner in Juniper who can deliver a reliable, flexible, and secure network across our facilities. This has in-turn allowed us to focus on supporting our production, research, development, and quality control operations – all crucial towards delivering our world-class APIs for critical pharma products utilized across the world,” said Manoranjan Jasti, chief information officer, Divi’s Labs.

According to the announcement, each site has already begun working with Juniper’s capabilities: this sees EXC4600 used as core/distribution switches, while EX3400 and EX2300 switches provide connectivity to critical network resources, including Wi-Fi access points.

In addition, Divi’s Labs data centers also fully runs on Juniper technology, which enables manufacturing processes, such as formula management, batch tracking, quality control, compliance tracking, and production scheduling.

Divi’s Labs manufacturing network is set to expand to include a third Indian site, in Andhra Pradesh. The company announced the facility in 2020, and provided an update in the latest announcement by confirming that the site is currently under construction.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more